Guardant Health's Shield test gains EviCore coverage in 2027
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
September 14, 2026 4:05 PM EDTSecond largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholders Milestone marks rapid adoption by insurers for the most clinically-validated blood test for CRC Increasing total covered Shield lives ages 45 and older to approximately 94 million, representing the overwhelming majority of eligible patients in the U.S.
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for... More
